Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kylee Maclachlan

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Journal of Hematology & Oncology|January 6, 2026
Multiple myeloma risk linked to DNA damage response genesMichael Conry, Irina Ostrovnaya, Yelena Kemel, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific AntibodiesIssam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.
American Journal of Hematology|January 2, 2023
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approachMatthew J Pianko, Timothy Tiutan, Andriy Derkach, et al.
JCO Oncology Practice|September 16, 2025
Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up DosesIssam S Hamadeh, Lisa Modelevsky, Amelia Chan, et al.
Blood Advances|April 10, 2024
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapyIssam S Hamadeh, Tala Shekarkhand, Colin Rueda, et al.
Hemasphere|September 25, 2025
Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myelomaJuan-Jose Garces, Benjamin Diamond, Tereza Sevcikova, et al.
Blood|May 10, 2024
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myelomaAnthony M Cirrincione, Alexandra M Poos, Bachisio Ziccheddu, et al.
Research Square|June 17, 2024
Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple MyelomaMalin Hultcrantz, Hani Hassoun, Neha Korde, et al.
The Lancet. Haematology|May 28, 2021
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trialBenjamin Diamond, Neha Korde, Alexander M Lesokhin, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Robust CD4<sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene AutoleucelEric M Jurgens, Sneha Mitra, Kevin Herrera, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Journal of Hematology & Oncology|January 6, 2026
Multiple myeloma risk linked to DNA damage response genesMichael Conry, Irina Ostrovnaya, Yelena Kemel, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific AntibodiesIssam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.
American Journal of Hematology|January 2, 2023
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approachMatthew J Pianko, Timothy Tiutan, Andriy Derkach, et al.
JCO Oncology Practice|September 16, 2025
Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up DosesIssam S Hamadeh, Lisa Modelevsky, Amelia Chan, et al.
Blood Advances|April 10, 2024
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapyIssam S Hamadeh, Tala Shekarkhand, Colin Rueda, et al.
Hemasphere|September 25, 2025
Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myelomaJuan-Jose Garces, Benjamin Diamond, Tereza Sevcikova, et al.
Blood|May 10, 2024
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myelomaAnthony M Cirrincione, Alexandra M Poos, Bachisio Ziccheddu, et al.
Research Square|June 17, 2024
Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple MyelomaMalin Hultcrantz, Hani Hassoun, Neha Korde, et al.
The Lancet. Haematology|May 28, 2021
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trialBenjamin Diamond, Neha Korde, Alexander M Lesokhin, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Robust CD4<sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene AutoleucelEric M Jurgens, Sneha Mitra, Kevin Herrera, et al.
Pageof 4